Trial Type: Colon Cancer

BrUOG 430
A Phase II Pilot Study Of Yttrium-90 In Combination With Capecitabine And Atezolizumab For Oligometastatic Colorectal Cancer With Unresectable Liver Metastases (METEORITE)
Status: Pending
Trial Type: Colon Cancer
Contact: Alex Raufi, MD
LS-P Path
A Phase 1 Open-Label Study of PF-07934040 as a Single-Agent and in Combination With Other Targeted Agents in Participants with Advanced Solid Tumors Harboring Mutations in the KRAS Gene.
Contact: Howard Safran, MD
GPC3CD3 Trial
A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors
Contact: Khaldoun Almhanna, MD
AZD0901
Anti claudin antibody drug conjugate AZD0901 for solid tumors expressing claudin 18.2 (Port trial)
Status: Open
Trial Type: Colon Cancer
Contact: Alex Raufi, MD
LS-P-AMORE
RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNNT1222-01)
Status: Open
Trial Type: Colon Cancer
Contact: Rimini Breakstone, MD
LS-P-OCEAN
A Phase 1, Two-Part, Multicenter, Open-Label First-in-Human Study of anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Solid Tumors
Status: Open
Trial Type: Colon Cancer
Contact: Rimini Breakstone, MD